HepaStem: Stem Cell Technology as a Potential Treatment for NASH and ACLF

Hepastem by Promethera Biosciences

ABOUT

CLIENT:

Promethera Biosciences is a global innovator in stem cell liver treatments and liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases.

More info at promethera.com

SERVICE:

Learn in the Stem Cell Animation below about the multiple modes of action of HepaStem and why the technology is ideal to promote immune modulation and reduce tissue fibrosis for devastating immune-mediated liver diseases.

HepaStem: a potential treatment of NASH and ACLF

HepaStem consists of liver-derived Mesenchymal Stem Cells that are obtained from ethically healthy donated organs and expanded in the lab. The treatment is ideal to calm down the immune system in case of acquired and chronic devastating liver diseases such as Acute on Chronic Liver Failure (ACLF) and Non- Alcoholic SteatoHepatitis (NASH).

Conclusion:
Promethera believes that HepaStem can be a treatment of nash and other serious acquired liver diseases primarily by decreasing the exaggerated systemic inflammation that the disease causes through the restoration of an immune balance and potential inhibition of bacterial growth that would help to resolve multiple organ failures.

In addition to the reduction of systemic inflammation, HepaStem could have a major impact on a patient’s liver through local anti-inflammatory effects. These effects, showns in a stem cell animation, could contribute to the restoration, at least partially, of the liver function by intercellular communication either through direct cell-to-cell contact or by paracrine signaling.

You can also check the video on their youtube channel.

RECENT POSTS